Rapid development of multiple drug resistance against current therapies is a major barrier
in the treatment of cancer. Therefore, anticancer agents that can overcome acquired drug …

IDH1 plays a critical role in a number of metabolic processes and serves as a key source of
cytosolic NADPH under conditions of cellular stress. However, few inhibitors of wild-type …

HA 14-1 is a small-molecule Bcl-2 antagonist that promotes apoptosis in malignant cells,
but its mechanism of action is not well defined. We recently reported that HA 14-1 has a half-life …

Prevention of relapse is a major therapeutic challenge and an unmet need for patients with
acute myeloid leukemia (AML). Venetoclax is a highly selective, potent, oral BCL-2 inhibitor …

Patients with hormone-refractory prostate cancer (HRPC) have an estimated median
survival of only 10 months because of acquired drug resistance, urging the need to develop …

Genome-wide CRISPR-Cas9 essentiality screening represents a powerful approach to identify
genetic vulnerabilities in cancer cells. Here, we applied this technology and designed a …

Background: Acute myeloid leukemia (AML) is an aggressive, heterogenous hematologic
malignancy with poor prognosis. For eligible patients, standard treatment includes intensive …

… Addo,7 Wellington L. Mendes,7 Amir T. Fathi8 … N Engl J Med. 2009; 361(13), 1235-1248.
4. … N ≈ 426 Stratified …

As part of a multi-year technology integration strategy to identify unprecedented targets,
AbbVie has committed to building broad-endpoint profiling assays to enable phenotypic …

The availability of high-quality RNA-sequencing and genotyping data of post-mortem brain
collections from consortia such as CommonMind Consortium (CMC) and the Accelerating …